Mer­ck pro­vid­ed some of the clear­est di­rec­tion yet re­gard­ing its am­bi­tions in on­col­o­gy to im­prove on its block­buster im­munother­a­py Keytru­da.

The com­pa­ny plans to con­duct...

If an­a­lysts and in­vestors think that Pfiz­er has a trick up its sleeve to fur­ther ac­quire its way to growth, CEO Al­bert Bourla as­sured them...

For the last few months, I've been watch­ing the de­bate about the US-Chi­na biotech ri­val­ry un­fold, and I've been un­sat­is­fied. There are great, smart peo­ple...

Is the era of the big phar­ma megamerg­er about to re­turn?

This week­end, the news broke that As­traZeneca and Bris­tol My­ers Squibb were al­leged­ly in...

For years, No­vo Nordisk and Eli Lil­ly have dom­i­nat­ed the con­ver­sa­tion sur­round­ing obe­si­ty med­i­cines as the du­op­oly com­petes to lead the largest phar­ma­ceu­ti­cal cat­e­go­ry in...

A year ago, the con­cept of an “AI doc­tor” was brand new. Now there are sev­er­al star­tups us­ing ar­ti­fi­cial in­tel­li­gence to han­dle pa­tient in­take for...